betaine has been researched along with Recrudescence in 3 studies
glycine betaine : The amino acid betaine derived from glycine.
Excerpt | Relevance | Reference |
---|---|---|
"We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke." | 8.02 | Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021) |
"We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke." | 4.02 | Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021) |
"Malignant hypertension was diagnosed." | 1.40 | Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. ( Benoist, JF; Cornec-Le Gall, E; De Parscau, L; Delmas, Y; Doucet, L; Fremeaux-Bacchi, V; Le Meur, Y; Ogier, H, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Zhong, C | 1 |
Miao, M | 1 |
Che, B | 1 |
Du, J | 1 |
Wang, A | 1 |
Peng, H | 1 |
Bu, X | 1 |
Zhang, J | 1 |
Ju, Z | 1 |
Xu, T | 1 |
He, J | 1 |
Zhang, Y | 1 |
Cornec-Le Gall, E | 1 |
Delmas, Y | 1 |
De Parscau, L | 1 |
Doucet, L | 1 |
Ogier, H | 1 |
Benoist, JF | 1 |
Fremeaux-Bacchi, V | 1 |
Le Meur, Y | 1 |
Herlofson, BB | 1 |
Barkvoll, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072] | 4,071 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months
Intervention | Participants (Count of Participants) |
---|---|
Usual Care | 502 |
Active Antihypertensive Treatment | 500 |
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks
Intervention | participants (Number) |
---|---|
Usual Care | 681 |
Active Antihypertensive Treatment | 683 |
Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months
Intervention | MoCA score (Median) |
---|---|
Usual Care | 22 |
Active Antihypertensive Treatment | 22 |
Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months
Intervention | MMSE score (Median) |
---|---|
Usual Care | 26 |
Active Antihypertensive Treatment | 26 |
Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months
Intervention | Score on modified Rankin scale (Median) |
---|---|
Usual Care | 1.0 |
Active Antihypertensive Treatment | 1.0 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months
Intervention | participants (Number) |
---|---|
Active Antihypertensive Treatment | 68 |
Usual Care | 54 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months
Intervention | participants (Number) |
---|---|
Usual Care | 59 |
Active Antihypertensive Treatment | 48 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months
Intervention | participants (Number) |
---|---|
Active Antihypertensive Treatment | 28 |
Usual Care | 43 |
1 trial available for betaine and Recrudescence
Article | Year |
---|---|
The effect of two toothpaste detergents on the frequency of recurrent aphthous ulcers.
Topics: Adolescent; Adult; Aged; Betaine; Child; Cross-Over Studies; Detergents; Double-Blind Method; Female | 1996 |
2 other studies available for betaine and Recrudescence
Article | Year |
---|---|
Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
Topics: Aged; Betaine; Cardiovascular Diseases; Case-Control Studies; Choline; Female; Humans; Lipotropic Ag | 2021 |
Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency.
Topics: Adult; Amino Acid Metabolism, Inborn Errors; Antibodies, Monoclonal, Humanized; Betaine; Biopsy; Car | 2014 |